| 前收盘价格 | 0.796 |
| 收盘价格 | 0.841 |
| 成交量 | 1,018,705 |
| 平均成交量 (3个月) | 673,703 |
| 市值 | 1,811,825,408 |
| 价格/销量 (P/S) | 914.87 |
| 股市价格/股市净资产 (P/B) | 97.15 |
| 52周波幅 | |
| 利润日期 | 17 Mar 2025 |
| 营业利益率 (TTM) | -67,856.58% |
| 稀释每股收益 (EPS TTM) | -0.620 |
| 总债务/股东权益 (D/E MRQ) | 0.81% |
| 流动比率 (MRQ) | 10.93 |
| 营业现金流 (OCF TTM) | -126.35 M |
| 杠杆自由现金流 (LFCF TTM) | -121.36 M |
| 资产报酬率 (ROA TTM) | -25.87% |
| 股东权益报酬率 (ROE TTM) | -41.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | ProKidney Corp. | 混合的 | 看涨 |
AIStockmoo 评分
0.4
| 分析师共识 | NA |
| 内部交易活动 | 2.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -4.0 |
| 平均 | 0.38 |
|
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 28.29% |
| 机构持股比例 | 44.35% |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 17 Mar 2025 | 公告 | ProKidney Reports Full Year 2024 Financial Results and Business Highlights |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合